Artificial Collaborates to Enhance COVID-19 Diagnostic Testing Solution
Summary
Under the terms of the agreement, Thermo Fisher Scientific secured early access to Artificial’s software, aLab Suite, to enhance the capabilities of their standardized COVID-19 Testing Platform. Artificial’s aLab Suite is intended to seamlessly integrate with Thermo Scientific’s Momentum workflow software and robotics hardware to enable laboratories to quickly scale COVID-19 testing to volumes needed for reducing the spread of disease and restoring economies and communities. Thermo Fisher Scientific will also provide feedback on aLab Suite functionalities and capabilities to contribute to future product requirements and system specifications. With their first-of-its-kind digital tools, our partnership with Artificial represents an exciting opportunity to meet the needs of rapidly scaling COVID-19 testing for the current pandemic,” said Hansjoerg Haas, senior director and General Manager, Laboratory Automation, Thermo Fisher Scientific. By bringing robotics, automation, data, and people together on a single easy-to-use platform, labs are empowered to go from scientific intent to reliable results faster and more efficiently.